BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] An unusual case of Candida tropicalis and Candida krusei arthritis in a patient with acute myelogenous leukemia before chemotherapy.

A 79-year-old male with acute myelogenous leukemia developed acute right knee arthritis during admission, after the use of broad-spectrum antibiotics before chemotherapy.

The initial synovial fluid sample appeared to be mildly inflammatory with a low white cell count.

The fungal septic arthritis was not diagnosed until Candida tropicalis, a rare species of Candida, was isolated in the synovial fluid.

Although fluconazole is effective in treating the microorganism, the untreated leukemia rendered the infection incurable and led to the growth of fluconazole-resistant Candida krusei.

[MeSH-major] Arthritis, Infectious / pathology. Candida / isolation & purification. Candidiasis / pathology. Leukemia, Myeloid, Acute / pathology

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Genetic Alliance. consumer health - Arthritis.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Infectious Arthritis.

MedlinePlus Health Information. consumer health - Yeast Infections.

Hazardous Substances Data Bank. FLUCONAZOLE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Infect Dis. 1997 Jun;24(6):1122-8 [9195068.001]

[Cites] Infection. 1997 Mar-Apr;25(2):109-11 [9108187.001]

[Cites] J Pediatr. 1975 Dec;87(6 Pt 1):989-90 [1059760.001]

[Cites] Rev Infect Dis. 1982 Jan-Feb;4(1):78-85 [6951237.001]

[Cites] Am J Med Sci. 1984 Jul-Aug;288(1):25-7 [6465189.001]

[Cites] J Hosp Infect. 2002 Apr;50(4):316-9 [12014908.001]

[Cites] Hong Kong Med J. 2005 Apr;11(2):120-3 [15815067.001]

[Cites] Semin Arthritis Rheum. 1993 Feb;22(4):224-41 [8484130.001]

[Cites] Am J Med. 1987 Nov;83(5):963-5 [3479022.001]

(PMID = 16767352.001).

[ISSN] 0770-3198

[Journal-full-title] Clinical rheumatology

[ISO-abbreviation] Clin. Rheumatol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antifungal Agents; 8VZV102JFY / Fluconazole

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Activating mutations of KIT play an important role in the pathophysiology of several human malignancies, including acute myeloid leukemia.

Here we examined the potency of a novel KIT inhibitor KI-328 against different types of mutant KIT kinases recurrently identified in AML.

Furthermore, HSP90 inhibitors suppress the growth of D816V-KIT-expressing cells at the concentration at which the growth of other mutant-KIT-expressing cells is not affected.

[MeSH-major] Antineoplastic Agents / pharmacology. Carbamates / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Mutation. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-kit / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / pharmacology

[MeSH-minor] Cell Line, Tumor. Humans. K562 Cells

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Bioorg Med Chem Lett. 2008 Oct 15;18(20):5472-7 [18835166.001]

[Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]

[Cites] Blood. 2002 Mar 1;99(5):1741-4 [11861291.001]

[Cites] Blood. 2006 May 1;107(9):3463-8 [16384925.001]

[Cites] Cell. 1991 Jun 28;65(7):1143-52 [1648448.001]

[Cites] Br J Dermatol. 2008 Nov;159(5):1160-9 [18795925.001]

[Cites] Blood. 2009 Aug 20;114(8):1607-17 [19541823.001]

[Cites] Br J Haematol. 2007 Jul;138(1):12-30 [17555444.001]

[Cites] Blood. 2004 Feb 1;103(3):1078-84 [14551138.001]

[Cites] Leukemia. 2009 Jan;23(1):95-103 [18830255.001]

[Cites] Clin Cancer Res. 2009 Jan 1;15(1):9-14 [19118027.001]

[Cites] Nat Rev Cancer. 2002 Jul;2(7):502-13 [12094236.001]

[Cites] Leukemia. 2000 Mar;14(3):374-8 [10720129.001]

[Cites] Eur J Haematol. 2009 Aug;83(2):90-8 [19309322.001]

[Cites] Nat Rev Cancer. 2005 Oct;5(10):761-72 [16175177.001]

[Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]

[Cites] J Biol Chem. 2008 Jul 4;283(27):18473-7 [18442971.001]

[Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]

[Cites] J Clin Oncol. 2005 Sep 10;23(26):6285-95 [16155011.001]

[Cites] Cancer Res. 2006 Jan 1;66(1):473-81 [16397263.001]

[Cites] Cancer Res. 2006 Sep 15;66(18):9153-61 [16982758.001]

[Cites] Blood. 2007 Jan 1;109(1):315-22 [16912224.001]

[Cites] Blood. 2004 Dec 1;104(12):3754-7 [15304388.001]

[Cites] Leukemia. 2002 Aug;16(8):1535-40 [12145695.001]

[Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]

[Cites] Blood. 2000 Jan 15;95(2):726-7 [10660321.001]

[Cites] Mol Cancer Ther. 2003 May;2(5):471-8 [12748309.001]

[Cites] Cancer Cell. 2003 Mar;3(3):213-7 [12676580.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7 [19164557.001]

[Cites] Blood. 1997 Aug 15;90(4):1345-64 [9269751.001]

[Cites] Lancet Oncol. 2005 Apr;6(4):249-51 [15811621.001]

[Cites] Biochem Biophys Res Commun. 2005 Dec 23;338(3):1307-15 [16226710.001]

[Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]

[Cites] Blood. 2005 Oct 15;106(8):2865-70 [15972446.001]

[Cites] J Biol Chem. 2003 Aug 22;278(34):31461-4 [12824176.001]

[Cites] Mol Cancer Ther. 2002 Oct;1(12):1115-24 [12481435.001]

[Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]

[Cites] J Clin Invest. 1993 Oct;92(4):1736-44 [7691885.001]

[Cites] Br J Cancer. 2009 May 19;100(10):1523-9 [19401686.001]

[Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4575-82 [17671144.001]

[Cites] PLoS One. 2009 Sep 30;4(9):e7258 [19789626.001]

[Cites] Blood. 1991 Dec 1;78(11):2962-8 [1720040.001]

[Cites] Stem Cells. 2005;23(1):16-43 [15625120.001]

(PMID = 20890793.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbamates; 0 / HSP90 Heat-Shock Proteins; 0 / KI 328; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Myeloid sarcoma of the prostate revealed by urinary retention: a case report.

Myeloid sarcoma (MS) of the prostate is very uncommon with only 17 reported cases in the literature.

Here, a singular case of a MS of the prostate discovered through investigations for urinary retention and revealing an acute leukaemia classified as an acute myeloid leukaemia (AML) with inversion 16 (inv16) according to the World Health Organization (WHO) classification (AML-M4 with inv16 in the French-American-British (FAB) classification) in a 65-year-old man is presented.

None of the previously reported and reviewed cases of prostatic MS were of AML-M4 type.

Such a translocation was recently described in some acute myeloid processes.

Radiation therapy could be beneficial for the localised disease of the prostate.

Allogenic haematopoietic stem cell transplantation is also a promising therapy for MS.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Haematologica. 1953;37(8):827-34 [13128526.001]

[Cites] Br J Surg. 1960 May;47:658-60 [13838365.001]

[Cites] Ann Hematol. 2004 Feb;83(2):78-83 [14551738.001]

[Cites] Lancet Oncol. 2004 Jan;5(1):62-3 [14700611.001]

[Cites] Cancer. 2006 Nov 1;107(9):2099-107 [17019734.001]

[Cites] Leuk Lymphoma. 2006 Dec;47(12):2527-41 [17169797.001]

[Cites] J Urol. 1947 Oct;58(4):272-6 [20266242.001]

[Cites] Ann Hematol. 1994 Feb;68(2):97-9 [8148423.001]

[Cites] Prog Urol. 1998 Sep;8(4):569-72 [9834524.001]

[Cites] Int Urol Nephrol. 2004;36(1):55-6 [15338675.001]

[Cites] Urol Oncol. 2005 Nov-Dec;23(6):419-21 [16301120.001]

[Cites] Br J Urol. 1990 Jun;65(6):655-6 [2372683.001]

[Cites] Cancer. 1987 Jan 1;59(1):142-6 [2431755.001]

[Cites] Cancer. 1970 Dec;26(6):1361-5 [4098491.001]

[Cites] G Gerontol. 1967 May;15(5):605-14 [5250187.001]

[Cites] Cancer. 1983 Jun 15;51(12):2164-7 [6573938.001]

[Cites] Am J Hematol. 1996 Dec;53(4):267-71 [8948669.001]

(PMID = 21686890.001).

[ISSN] 1757-790X

[Journal-full-title] BMJ case reports

[ISO-abbreviation] BMJ Case Rep

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC3029613

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] beta-Tryptase up-regulates vascular endothelial growth factor expression via proteinase-activated receptor-2 and mitogen-activated protein kinase pathways in bone marrow stromal cells in acute myeloid leukemia.

Tryptases are predominantly mast cell-specific serine proteases with pleiotropic biological activities.

Recently, significant amounts of tryptases have been shown to be produced by myeloblasts in certain patients with acute myeloid leukemia (AML), but the function of secreted tryptases in pathological circumstances remains unknown.

In this study, we investigated whether beta-tryptase affects the expression of vascular endothelial growth factor (VEGF) in bone marrow stromal cells (BMSCs) in AML.

We detected the expression of proteinase-activated receptor-2 (PAR-2) on AML BMSCs and found that beta-tryptase significantly up-regulated VEGF mRNA and protein expression in a dose-dependent manner by real-time PCR, Western blot, and ELISA.

These results suggest that beta-tryptase up-regulates VEGF production in AML BMSCs via the PAR-2, ERK1/2, and p38MAPK signaling pathways.

[MeSH-major] Bone Marrow Cells / metabolism. Leukemia, Myeloid, Acute / metabolism. Leukemia, Promyelocytic, Acute / metabolism. Mitogen-Activated Protein Kinases / metabolism. Receptor, PAR-2 / metabolism. Stromal Cells / metabolism. Tryptases / metabolism. Vascular Endothelial Growth Factor A / metabolism

[MeSH-minor] Blotting, Western. Cell Proliferation. Cells, Cultured. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Humans. Immunoenzyme Techniques. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Up-Regulation

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20578818.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, PAR-2; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.21.59 / Tryptases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

DNA methylation of CpG islands around gene transcription start sites results in gene silencing and plays a role in leukemia pathophysiology.

Its impact in leukemia progression is not fully understood.

We performed genomewide screening for methylated CpG islands and identified 8 genes frequently methylated in leukemia cell lines and in patients with acute myeloid leukemia (AML): NOR1, CDH13, p15, NPM2, OLIG2, PGR, HIN1, and SLC26A4.

We assessed the methylation status of these genes and of the repetitive element LINE-1 in 30 patients with AML, both at diagnosis and relapse.

Abnormal methylation was found in 23% to 83% of patients at diagnosis and in 47% to 93% at relapse, with CDH13 being the most frequently methylated.

We observed concordance in methylation of several genes, confirming the presence of a hypermethylator pathway in AML.

DNA methylation levels increased at relapse in 25 of 30 (83%) patients with AML.

These changes represent much larger epigenetic dysregulation, since methylation microarray analysis of 9008 autosomal genes in 4 patients showed hypermethylation ranging from 5.9% to 13.6% (median 8.3%) genes at diagnosis and 8.0% to 15.2% (median 10.6%) genes in relapse (P < .001).

Our data suggest that DNA methylation is involved in AML progression and provide a rationale for the use of epigenetic agents in remission maintenance.

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2001 May 1;97(9):2823-9 [11313277.001]

[Cites] Cancer Res. 2007 Mar 1;67(5):1997-2005 [17332327.001]

[Cites] Blood. 2002 Oct 15;100(8):2957-64 [12351408.001]

[Cites] J Clin Oncol. 2003 Apr 15;21(8):1472-9 [12697869.001]

[Cites] Blood. 2003 May 15;101(10):4131-6 [12586619.001]

[Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]

[Cites] Clin Cancer Res. 2003 Aug 1;9(8):2879-81 [12912930.001]

[Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]

[Cites] Cancer Res. 2004 Apr 1;64(7):2411-7 [15059893.001]

[Cites] FEBS Lett. 2004 Jun 4;567(2-3):327-32 [15178346.001]

[Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]

[Cites] Cancer Res. 1996 Feb 15;56(4):722-7 [8631003.001]

[Cites] Cancer Res. 1996 Mar 1;56(5):973-77 [8640788.001]

[Cites] J Mol Biol. 1996 Nov 29;264(2):268-78 [8951376.001]

[Cites] Cancer Res. 1999 May 15;59(10):2307-12 [10344734.001]

[Cites] Cancer Res. 1999 Jul 15;59(14):3352-6 [10416592.001]

[Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]

[Cites] Nat Genet. 2005 Mar;37(3):265-74 [15723065.001]

[Cites] Br J Cancer. 2005 Mar 28;92(6):1165-72 [15756280.001]

[Cites] J Clin Oncol. 2005 Jun 10;23(17):3948-56 [15883410.001]

[Cites] Mol Cancer Res. 2005 Jun;3(6):325-34 [15972851.001]

[Cites] J Clin Oncol. 2005 Sep 10;23(26):6285-95 [16155011.001]

[Cites] J Clin Oncol. 2005 Oct 1;23(28):7043-9 [16192589.001]

[Cites] Semin Oncol. 2005 Oct;32(5):521-30 [16210093.001]

[Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]

[Cites] Ann Hematol. 2005 Dec;84 Suppl 1:39-46 [16231140.001]

[Cites] Br J Haematol. 2006 May;133(3):276-83 [16643429.001]

[Cites] Cancer Res. 2006 May 15;66(10):5077-84 [16707430.001]

[Cites] Clin Cancer Res. 2006 Aug 15;12(16):4845-50 [16914570.001]

[Cites] Br J Cancer. 2006 Oct 23;95(8):1108-13 [17047656.001]

[Cites] Blood. 2007 Jan 1;109(1):52-7 [16882708.001]

[Cites] Cancer Res. 2007 Feb 1;67(3):876-80 [17283117.001]

[Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]

[Cites] Blood. 2007 May 1;109(9):3895-905 [17234736.001]

[Cites] Genome Res. 2007 Oct;17(10):1529-36 [17785535.001]

[Cites] PLoS Genet. 2007 Oct;3(10):2023-36 [17967063.001]

[Cites] Oncogene. 2002 Apr 18;21(17):2741-9 [11965547.001]

(PMID = 18523155.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA108631; United States / NCI NIH HHS / CA / P50 CA100632; United States / NCI NIH HHS / CA / 5P01CA108631-03; United States / NCI NIH HHS / CA / 5P50CA100632-05

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Other-IDs] NLM/ PMC2515110

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Evaluation of oxidative status and depression-like responses in Brown Norway rats with acute myeloid leukemia.

It has been proved that oxidative stress increases when leukemia is accompanied by depression.

The aim of this study was to determine whether the acute myeloid leukemia of Brown Norway rats, which is accompanied by oxidative stress, evoked behavioral and receptor changes resembling alterations characteristic of rat models of depression.

Leukemia was induced through intraperitoneal injection of 10(7) promyelocytic leukemia cells to the Brown Norway rats.

Radioligand binding assay was used to assess of the effect of leukemia on cortical receptors.

Leukemia influenced locomotory activity as well as forced swim test behavior in a 34-day series of experiments.

Signs of oxidative stress in leukemic rats were observed in each examined stage of leukemia development.

Upregulation of 5-HT(2A) receptors was observed in rat cortex after 30 days of leukemia development but not in 34-days series compared with the control.

It is concluded that disturbances in antioxidant system in brain cortex were accompanied by an activation of glycine sites of the NMDA receptor complex, regardless of stage of leukemia development, which are characteristic of model of depression.

Findings of our study demonstrate the link between glutamatergic activity, oxidative stress and leukemia.

[MeSH-major] Depression / etiology. Disease Models, Animal. Leukemia, Myeloid, Acute / complications. Oxidative Stress / physiology

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Depression.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19268504.001).

[ISSN] 1878-4216

[Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry

[ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry

[Language] eng

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Receptors, Biogenic Amine; 9007-73-2 / Ferritins; EC 1.14.99.3 / Heme Oxygenase (Decyclizing); GAN16C9B8O / Glutathione; O9MIA842K9 / Biliverdine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.

Relapse of acute myelogenous leukemia has been associated with clonal cytogenetic evolution, but no study focused specifically on relapse after allogeneic hematopoietic stem cell transplantation (HSCT).

We compared karyotypes in 160 patients at both diagnosis and relapse either after allo-HSCT (n = 26) or standard chemotherapy (n = 134) using chromosome banding analysis combined with fluorescein in situ hybridization.

At diagnosis, aberrant karyotypes were more frequent in the HSCT than in the chemotherapy cohort (16 of 26; 61.5% versus 63 of 134; 47.0%).

Differences in the karyotypes between diagnosis and relapse were more frequent in the allo-cohort (14 of 26; 53.8% versus 49 of 134; 36.6%) than in the conventional cohort (n.s.

The mean number of cytogenetic alterations per patient was increasing from 2.0 at diagnosis to 4.0 at relapse in the allo-cohort, in the conventionally treated patients from 0.9 to 1.3 (both P < .001).

Thus, higher frequencies of clonal evolution and increasing cytogenetic complexity were observed in the stem cell recipients probably related to the more unfavorable cytogenetic profiles already depicted at diagnosis.

[MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

(PMID = 20558312.001).

[ISSN] 1523-6536

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genetic parameter estimates of meat quality traits in Duroc pigs selected for average daily gain, longissimus muscle area, backfat thickness, and intramuscular fat content.

Using a multitrait animal model BLUP, selection was conducted over seven generations for growth rate (ADG), real-time ultrasound LM area (LMA), backfat thickness (BF), and intramuscular fat content (IMF) to develop a new line of purebred Duroc pigs with enhanced meat production and meat quality.

Genetic correlations of IMF with ADG and BF were low and positive, but low and negative with LMA.

Tenderness was correlated negatively with ADG (-0.44) and BF (-0.59), but positively correlated with LMA (0.32).

The genetic correlation between LMA and DL was positive and high (0.64).

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16100060.001).

[ISSN] 1525-3163

[Journal-full-title] Journal of animal science

[ISO-abbreviation] J. Anim. Sci.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 9007-34-5 / Collagen

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia.

Traditionally, patients with acute leukaemia are admitted to hospital during chemotherapy-induced pancytopenia, although a few recent reports have reported the feasibility and safety of outpatient treatment.

We have developed an outpatient treatment programme for patients with acute leukaemia incorporating comprehensive patient education for self-care management at home during pancytopenia and involvement of patients in care of their tunnelled central venous catheter (CVC).

Herein, we report the results of outpatient treatment of 60 patients with acute leukaemia (54 with acute myeloid leukaemia) followed prospectively in the period from March 2004 to 2007.

We conclude that outpatient treatment of patients with acute leukaemia is feasible and safe.

[MeSH-major] Ambulatory Care / methods. Anti-Infective Agents / administration & dosage. Leukemia / drug therapy. Neutropenia / drug therapy. Pancytopenia / drug therapy

[MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prospective Studies

MedlinePlus Health Information. consumer health - Childhood Leukemia.

MedlinePlus Health Information. consumer health - Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20002732.001).

[ISSN] 1600-0609

[Journal-full-title] European journal of haematology

[ISO-abbreviation] Eur. J. Haematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Anti-Infective Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.

Acute myeloid leukemia (AML) remains the most common form of leukemia and the most common cause of leukemia death.

Although conventional chemotherapy can cure between 25 and 45% of AML patients, the majority of patients die after relapse or of complications associated with treatment.

Thus, more specific and less toxic treatments for AML patients are needed, especially for elderly patients.

An indispensable prerequisite to investigate tailored approaches for AML is the recent progress in the understanding the molecular features that distinguish leukemia progenitors from normal hematopoietic counterparts and the identification of a variety of dysregulated molecular pathways.

In this review, we describe some of the signaling pathways that are aberrantly regulated in AML, with a specific focus on their pathogenetic and therapeutic significance, and we examine some recent therapies directed against these targets, used in clinical trial for relapsed patients or unfit for conventional chemotherapy.

[MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Signal Transduction / drug effects

[MeSH-minor] Antineoplastic Agents / pharmacology. Drug Design. Genetic Predisposition to Disease / genetics. Humans. Immunologic Factors / pharmacology. Remission Induction. Translocation, Genetic

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18534059.001).

[ISSN] 1607-8454

[Journal-full-title] Hematology (Amsterdam, Netherlands)

[ISO-abbreviation] Hematology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases

[Number-of-references] 126

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.

This is the first study of FLT3 mutations in pediatric non-promyelocytic AML patients that received the same treatment scheme in single institute.

Patients with FLT3/TKD remain alive after autologous stem cell transplantation.

The disease-free survival (DFS) of patients with FLT3/ITD (0%) was significantly lower than that of the others (52%).

New therapeutic scheme such as stem cell transplantation with more intensive conditioning just after complete remission could be applied in pediatric non-promyelocytic AML patients with the FLT3/ITD mutation.

[MeSH-major] Leukemia, Myeloid, Acute / genetics. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15863200.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Leukemia regression by vascular disruption and antiangiogenic therapy.

Acute myelogenous leukemias (AMLs) and endothelial cells depend on each other for survival and proliferation.

Monotherapy antivascular strategies such as targeting vascular endothelial growth factor (VEGF) has limited efficacy in treating AML.

Thus, in search of a multitarget antivascular treatment strategy for AML, we tested a novel vascular disrupting agent, OXi4503, alone and in combination with the anti-VEGF antibody, bevacizumab.

Using xenotransplant animal models, OXi4503 treatment of human AML chloromas led to vascular disruption in leukemia cores that displayed increased leukemia cell apoptosis.

However, viable rims of leukemia cells remained and were richly vascular with increased VEGF-A expression.

To target this peripheral reactive angiogenesis, bevacizumab was combined with OXi4503 and abrogated viable vascular rims, thereby leading to enhanced leukemia regression.

In a systemic model of primary human AML, OXi4503 regressed leukemia engraftment alone and in combination with bevacizumab.

Differences in blood vessel density alone could not account for the observed regression, suggesting that OXi4503 also exhibited direct cytotoxic effects on leukemia cells.

Together, these data show that OXi4503 alone is capable of regressing AML by a multitargeted mechanism and that the addition of bevacizumab mitigates reactive angiogenesis.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2000 Jan 1;95(1):309-13 [10607717.001]

[Cites] Br J Cancer. 1999 Dec;81(8):1318-27 [10604728.001]

[Cites] Blood. 1997 Mar 15;89(6):1870-5 [9058706.001]

[Cites] Am J Pathol. 1997 Mar;150(3):815-21 [9060819.001]

[Cites] Cancer Res. 1997 May 15;57(10):1829-34 [9157969.001]

[Cites] Anticancer Res. 1999 Jan-Feb;19(1A):189-95 [10226542.001]

[Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]

[Cites] J Clin Oncol. 2005 Feb 20;23(6):1109-17 [15718307.001]

[Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]

[Cites] Hematology. 2005 Dec;10(6):483-94 [16321813.001]

[Cites] Clin Cancer Res. 2006 Jul 1;12(13):4090-4 [16818709.001]

[Cites] Haematologica. 2006 Sep;91(9):1203-11 [16956819.001]

[Cites] Int J Cancer. 2006 Nov 15;119(10):2313-21 [16921487.001]

[Cites] Bioorg Med Chem. 2007 Jan 15;15(2):605-15 [17070061.001]

[Cites] Leukemia. 2007 Jun;21(6):1310-2 [17330095.001]

[Cites] Stem Cells. 2007 Aug;25(8):1862-71 [17446561.001]

[Cites] Chem Res Toxicol. 2007 Dec;20(12):1885-94 [17941699.001]

[Cites] Blood. 2008 Feb 15;111(4):1951-61 [18024794.001]

[Cites] Leukemia. 2008 Feb;22(2):287-93 [17943167.001]

[Cites] Anticancer Res. 2008 Jul-Aug;28(4B):2027-31 [18751370.001]

[Cites] Cell Tissue Res. 2009 Jan;335(1):241-8 [18752004.001]

[Cites] Br J Haematol. 2009 Jan;144(1):53-68 [19016730.001]

[Cites] Expert Opin Investig Drugs. 2009 Feb;18(2):189-97 [19236265.001]

[Cites] Stem Cells Dev. 2009 Oct;18(8):1235-42 [19105599.001]

[Cites] Expert Opin Investig Drugs. 2010 Feb;19(2):169-83 [20050812.001]

[Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]

[Cites] Blood. 2001 Apr 1;97(7):2121-9 [11264180.001]

[Cites] Anticancer Res. 2001 Jan-Feb;21(1A):93-102 [11299795.001]

[Cites] Blood. 2000 Apr 15;95(8):2637-44 [10753845.001]

[Cites] Leukemia. 2001 Sep;15(9):1369-76 [11516097.001]

[Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62 [11553814.001]

[Cites] Blood. 2002 Mar 15;99(6):2060-9 [11877280.001]

[Cites] Blood. 2002 Mar 15;99(6):2179-84 [11877295.001]

[Cites] Acta Oncol. 2002;41(1):98-105 [11990526.001]

[Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]

[Cites] Leukemia. 2002 Jul;16(7):1302-10 [12094254.001]

[Cites] Anticancer Res. 2002 May-Jun;22(3):1453-8 [12168822.001]

[Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]

[Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1433-40 [12820406.001]

[Cites] Blood. 2003 Oct 15;102(8):2763-7 [12843001.001]

[Cites] Clin Cancer Res. 2004 Jun 1;10(11):3577-85 [15173063.001]

[Cites] Cancer. 2004 Jun 15;100(12):2491-9 [15197790.001]

[Cites] Leuk Lymphoma. 2004 Jul;45(7):1369-73 [15359635.001]

[Cites] Leuk Lymphoma. 2004 Jun;45(6):1185-90 [15359999.001]

[Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]

[Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]

[Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]

[Cites] Blood. 1999 Dec 1;94(11):3717-21 [10572084.001]

[CommentIn] Blood. 2010 Sep 2;116(9):1389-90 [20813902.001]

(PMID = 20472832.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NIDDK NIH HHS / DK / K08 DK067359; United States / NCI NIH HHS / CA / CA084408; United States / NCI NIH HHS / CA / CA089655; United States / NCI NIH HHS / CA / R01 CA089655; United States / NHLBI NIH HHS / HL / R01 HL070738; United States / NCI NIH HHS / CA / R01 CA084408

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Diphosphates; 0 / Il2rg protein, mouse; 0 / Interleukin Receptor Common gamma Subunit; 0 / Oxi 4503; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Stilbenes; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab

[Other-IDs] NLM/ PMC2938842

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

Familial platelet disorder (FPD), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet abnormalities, is considered as a model of genetic predisposition to acute myeloid leukemia (AML).

So far, monoallelic RUNX1 germline mutations have been found in 19 of 20 families with reported FPD, and the analysis of blast cells from only 5 patients at acute leukemia (AL) stage has shown no additional RUNX1 abnormality.

In addition to the germline RUNX1 mutation, we identified a second RUNX1 alteration in 6 AML cases (acquired point mutations in 4 cases and duplication of the altered RUNX1 allele associated with acquired trisomy 21 in 2 other cases).

Although haploinsufficiency of RUNX1 causes FPD, our findings suggest that a second genetic event involving RUNX1 is often associated with progression to AML.

[MeSH-major] Blood Platelet Disorders / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Leukemia, Myeloid, Acute / genetics

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Platelet Disorders.

SciCrunch. OMIM: Data: Gene Annotation .

SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19357396.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pseudohypopyon: Extramedullary relapse of acute myelogenous leukemia with poor prognosis.

She was diagnosed with acute myelogenous leukemia.

[MeSH-major] Anterior Chamber / pathology. Eye Diseases / diagnosis. Leukemia, Myelomonocytic, Acute / diagnosis. Neoplasm Recurrence, Local / diagnosis

[MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. Female. Humans. Infant. Injections, Spinal. Prognosis. Suppuration / diagnosis

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

MedlinePlus Health Information. consumer health - Eye Diseases.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley-Liss, Inc.

(PMID = 19090546.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute myeloid leukaemia diagnosed by intra-oral myeloid sarcoma. A case report.

Myeloid sarcoma (MS) is a rare extramedullary malignant tumor composed of immature myeloid cells.

It is strongly associated with a well known or covert acute myeloid leukaemia, chronic myeloproliferative diseases or myelodysplastic syndromes.

An unusual case of acute myeloid leukaemia, which was diagnosed by mandibular MS that was developed in the alveolar socket after a dental extraction, is reported.

The histological examination (including immunohistochemical analysis) of a subsequent biopsy showed infiltration of the oral mucosa by neoplastic cells.

This lesion was therefore classified as acute myeloid leukaemia.

The patient was referred to oncologists that confirmed the initial diagnosis.

Forty days later, a relapse of the disease, which appeared as a great-ulcerated lesion, was developed in the hard palate.

Review of the literature shows no report of intraoral relapse and particularly multiple relapse of a MS that involves the oral cavity.

Even though MS is encountered infrequently in the oral cavity, it should be considered in the differential diagnosis of conditions (especially tumors) with a similar clinical appearance.

[MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary / diagnosis. Sarcoma, Myeloid / diagnosis

[MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Etoposide / therapeutic use. Fatal Outcome. Female. Humans. Mouth Mucosa / pathology. Mouth Neoplasms

Genetic Alliance. consumer health - Myeloid sarcoma.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. ETOPOSIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Oral Maxillofac Surg. 1990 Jul;48(7):748-52 [2193130.001]

[Cites] Leuk Res. 2004 Jan;28(1):25-34 [14630077.001]

[Cites] J Periodontol. 2003 Oct;74(10):1514-9 [14653399.001]

[Cites] Quintessence Int. 2007 Nov-Dec;38(10):817-20 [18197320.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jan;105(1):e34-6 [18155599.001]

[Cites] Isr Med Assoc J. 2003 Jun;5(6):452 [12841024.001]

[Cites] Oral Oncol. 2002 Jul;38(5):516-9 [12110349.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Dec;92(6):689-93 [11740487.001]

[Cites] Oral Oncol. 2000 Sep;36(5):491-4 [10964059.001]

[Cites] Int J Hematol. 2005 Feb;81(2):138-41 [15765782.001]

[Cites] J Oral Maxillofac Surg. 1991 Dec;49(12):1346-50 [1955927.001]

[Cites] Pediatr Blood Cancer. 2007 Apr;48(4):393-8 [16550530.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):e44-8 [17428693.001]

(PMID = 20512638.001).

[ISSN] 1936-0568

[Journal-full-title] Head and neck pathology

[ISO-abbreviation] Head Neck Pathol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide

[Other-IDs] NLM/ PMC2878628

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] In vitro generation of tumor specific T cells that recognize a shared antigen of AML: molecular characterization of TCR genes.

We present data demonstrating in vitro induction of autologous acute myelogenous leukemia (AML)-specific CTL.

The specific T cell receptor has been identified and cloned.

The CTL demonstrated specific lysis to autologous tumor blasts, but not to autologous BLCL or the NK-sensitive target K562.

The clone secreted GM-CSF, TNFa, and IFNg when stimulated with AML blasts from 3 of 11 patients or cell lines tested, but not with K562 or autologous B-LCL.

These three AML samples share a single HLA Class I antigen, HLA-A24.

The T cell receptor genes identified by molecular methods are Vbeta7.9-J2.3-Cbeta2 and Valpha17-J49-Calpha.

[MeSH-major] Antigens, Neoplasm / immunology. HLA Antigens / immunology. Leukemia, Myeloid / immunology. Receptors, Antigen, T-Cell / genetics. T-Lymphocytes, Cytotoxic / immunology

[MeSH-minor] Acute Disease. Amino Acid Sequence. CD8-Positive T-Lymphocytes / immunology. Cell Line, Tumor. Humans. Molecular Sequence Data

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Leuk Res. 2007 Feb;31(2):127-8 [17137625.001]

(PMID = 16750565.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA Antigens; 0 / Receptors, Antigen, T-Cell

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.

BACKGROUND: Wilms tumor 1 (WT1) is a transcription factor that is overexpressed in most acute myeloid leukemias (AMLs).

Recently, 2 groups reported that WT1 mutations occur in approximately 10% of normal karyotype AMLs and are an independent predictor of poor outcome in this subgroup of patients with AML.

METHODS: The authors studied a cohort of 268 young adults (ages 15-50 years) with AML who were treated on the Acute Leukemia French Association 9802 trial.

Within the subgroup of patients who had normal karyotype AML (n = 106), WT1 mutation was identified as an independent adverse prognostic factor for the risk of recurrence.

CONCLUSIONS: The current results indicted that WT1 mutations represent an adverse prognostic factor in young adults with AML.

Prospective trials should confirm the clinical relevance of WT1 mutations in relation to other prognostic factors in patients with AML.

[MeSH-major] Genes, Wilms Tumor. Leukemia, Myeloid, Acute / genetics

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19536888.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Willow leaves' extracts contain anti-tumor agents effective against three cell types.

Many non-natural, synthetic drugs cause severe side effects that were not acceptable except as treatments of last resort for terminal diseases such as cancer.

In vitro the willow extract could kill the majority (75%-80%) of abnormal cells among primary cells harvested from seven patients with acute lymphoblastic leukemia (ALL) and 13 with AML (acute myeloid leukemia).

DNA fragmentation patterns within treated cells inferred targeted cell death by apoptosis had occurred.

The metabolites within the willow extract may act as tumor inhibitors that promote apoptosis, cause DNA damage, and affect cell membranes and/or denature proteins.

[MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor / drug effects. Plant Extracts / pharmacology. Plant Leaves / chemistry. Salix

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Exp Cell Res. 1999 May 25;249(1):109-15 [10328958.001]

[Cites] Nutr Rev. 1998 Nov;56(11):317-33 [9838798.001]

[Cites] Nat Biotechnol. 2000 Nov;18(11):1157-61 [11062433.001]

[Cites] J Nutr. 2002 Jul;132(7):2076-81 [12097696.001]

[Cites] J Biochem Mol Biol. 2002 May 31;35(3):337-42 [12297018.001]

[Cites] Annu Rev Cell Dev Biol. 2002;18:515-39 [12142269.001]

[Cites] J Biochem Mol Biol. 2003 Jul 31;36(4):387-9 [12895297.001]

[Cites] Pharm Acta Helv. 1972 Mar-Apr;47(3):222-34 [5031927.001]

[Cites] Science. 1976 Feb 13;191(4227):571-2 [1251193.001]

[Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]

[Cites] Pharmazie. 1989 Aug;44(8):555-8 [2594827.001]

[Cites] Lancet. 1992 Jun 20;339(8808):1523-6 [1351198.001]

[Cites] J Pharm Sci. 1993 Apr;82(4):399-403 [8468684.001]

[Cites] Science. 1994 Apr 22;264(5158):532-7 [8160011.001]

[Cites] BMJ. 1995 May 6;310(6988):1165-9 [7767150.001]

[Cites] Science. 1997 Jan 10;275(5297):218-20 [8985016.001]

[Cites] N Engl J Med. 1997 Nov 20;337(21):1491-9 [9366580.001]

[Cites] Blood. 1998 Aug 1;92(3):996-1002 [9680369.001]

[Cites] J Clin Pharmacol. 2000 May;40(5):445-50 [10806595.001]

(PMID = 17264881.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Benzyl Alcohols; 0 / Glucosides; 0 / Plant Extracts; 4649620TBZ / salicin; FA1N0842KB / salicyl alcohol

[Other-IDs] NLM/ PMC1779808

[General-notes] NLM/ Original DateCompleted: 20070723

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia.

The mechanisms underlying deregulation of HOX gene expression in AML are poorly understood.

Deletion of the N-terminal domain of Cdx2 abrogated its ability to perturb Hox gene expression and to cause acute myeloid leukemia (AML) in mice.

In contrast inactivation of the putative Pbx interacting site of Cdx2 did not change the leukemogenic potential of the gene.

In an analysis of 115 patients with AML, expression levels of CDX2 were closely correlated with deregulated HOX gene expression.

All patients with AML with normal karyotype tested were negative for CDX1 and CDX4 expression.

They furthermore correlate the level of CDX2 expression with HOX gene expression in human AML and support a potential role of CDX2 in the development of human AML with aberrant Hox gene expression.

[MeSH-major] Gene Expression Regulation, Leukemic. Homeodomain Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Transcription Factors / genetics

[MeSH-minor] Adult. Animals. Bone Marrow Cells / cytology. Bone Marrow Cells / physiology. Bone Marrow Transplantation. Cell Line, Tumor. Gene Expression Profiling. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / physiology. Humans. Karyotyping. Mice. Mutagenesis. NIH 3T3 Cells. Protein Structure, Tertiary. Translocation, Genetic. Up-Regulation / physiology

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17855634.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CDX2 protein, human; 0 / Cdx2 protein, mouse; 0 / Homeodomain Proteins; 0 / Transcription Factors

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.

BACKGROUND: Valspodar, a non-immunosuppressive analog of cylosporine, is a potent P-glycoprotein (MDR1) inhibitor.

As MDR1-mediated efflux of chemotherapeutic agents from leukemic blasts may contribute to drug resistance, a phase 1 study of valspodar combined with mitoxantrone and etoposide in pediatric patients with relapsed or refractory leukemias was performed.

Three of 11 patients with acute lymphoblastic leukemia (ALL) had complete responses while no patient with acute myeloid leukemia (AML) had an objective response.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. NOVANTRONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leukemia. 2000 Aug;14(8):1436-43 [10942240.001]

[Cites] Blood. 2007 May 15;109(10):4168-70 [17227830.001]

[Cites] J Clin Oncol. 2001 Feb 1;19(3):832-42 [11157037.001]

[Cites] Leukemia. 2001 May;15(5):764-71 [11368437.001]

[Cites] Blood. 2001 Aug 15;98(4):988-94 [11493443.001]

[Cites] Hematol J. 2000;1(6):411-21 [11920222.001]

[Cites] Leukemia. 2002 May;16(5):920-7 [11986955.001]

[Cites] Leuk Lymphoma. 2002 Feb;43(2):309-14 [11999562.001]

[Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]

[Cites] J Clin Oncol. 2003 Dec 1;21(23):4377-85 [14645428.001]

[Cites] Clin Cancer Res. 2004 May 15;10(10):3265-72 [15161679.001]

[Cites] J Histochem Cytochem. 1977 Jul;25(7):935-41 [894009.001]

[Cites] Cancer Chemother Pharmacol. 1990;25(5):361-6 [2155063.001]

[Cites] Cancer Res. 1991 Sep 1;51(17):4665-70 [1873811.001]

[Cites] Cell. 1992 Oct 2;71(1):23-32 [1382860.001]

[Cites] J Clin Oncol. 1992 Oct;10(10):1635-42 [1403041.001]

[Cites] Anticancer Drugs. 1992 Dec;3(6):641-6 [1363199.001]

[Cites] Blood. 1993 May 1;81(9):2215-22 [8097632.001]

[Cites] Blood. 1996 Jun 1;87(11):4809-16 [8639853.001]

[Cites] Cancer Res. 1996 Jul 1;56(13):3010-20 [8674056.001]

[Cites] Blood. 1996 Jul 1;88(1):309-18 [8704189.001]

[Cites] Semin Hematol. 1997 Oct;34(4 Suppl 5):40-7 [9408960.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2004;:118-45 [15561680.001]

[Cites] Leukemia. 2005 Feb;19(2):176-82 [15592433.001]

[Cites] Clin Cancer Res. 2005 Mar 15;11(6):2320-6 [15788683.001]

[Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]

[Cites] Blood. 2006 Feb 15;107(4):1315-24 [16254147.001]

[Cites] Blood. 2006 Jun 15;107(12):4975-6; author reply 4976-7 [16754781.001]

[Cites] Curr Med Chem. 2006;13(16):1859-76 [16842198.001]

[Cites] Leuk Lymphoma. 2007 Apr;48(4):708-15 [17454628.001]

[Cites] Curr Opin Oncol. 2000 Sep;12(5):450-8 [10975553.001]

(PMID = 20209646.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA052168-12S1; United States / NCI NIH HHS / CA / U10 CA98413; United States / PHS HHS / / R01 52168; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCRR NIH HHS / RR / M01 RR 00070; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA052168; United States / NCRR NIH HHS / RR / M01 RR000070; United States / NCI NIH HHS / CA / U10 CA98543

[Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Cyclosporins; 0 / P-Glycoprotein; 121584-18-7 / valspodar; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone

[Other-IDs] NLM/ NIHMS155713; NLM/ PMC2838930

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Relationship between GSTT1, GSTM1 and NQO1 gene polymorphism and acute myeloid leukemia and recurrent chromosome translocations].

OBJECTIVE: To investigate the impact of GSTM1, GSTT1 and NQO1 genotypes on susceptibility to acute myeloid leukemia (AML) and recurrent chromosome translocations of AML.

METHODS: GSTT1, GSTM1 and NQO1 genotypes were detected in 228 adult patients with de novo AML and 241 controls by PCR or PCR-RFLP.

RESULTS: The frequency of GSTM1 null genotype in the AML patients was 62.3%, significantly higher than that in the normal controls (52.7%, P = 0.036), however, no significant difference was found in the incidence of GSTT1 null genotype.

The frequencies of NQO1(C609T) C/T and T/T genotypes were 53.1% and 25.0% respectively among the total AML patients (53.1% and 25.0% respectively), 64.3% and 25.0% respectively among the AML patients with t (8;.

21) (q22; q22)/AML-ETO fusion gene, and 57.1% and 26.0% respectively among the AML patient with t (15;.

21) (q22; q22)/AML-ETO (+) AML was 4.487 (95% CI: 1.282-15.705) for the subjects with NQO1(C609T) C/T genotype, and was 6.293 (95% CI: 1.536-25.782) for the subjects with NQO1(C609T) T/T genotype.

17) (q22; q11)/PML-RARalpha (+) AML was 2.531 (95% CI: 1.286-4.981) for the subjects with NQO1(C609T) C/T genotype, and was 4.149 (95% CI: 1.856-9.275) for the subjects with NQO1(C609T) T/T genotype.

CONCLUSION: Determination of the NQO1(C609T) genotypes may be used as a stratification marker to predict high-risk individuals for AML, especially for AML with t (8;.

21) (q22; q22)/AML-ETO fusion gene and t (15;.

[MeSH-major] Chromosome Aberrations. Glutathione Transferase / genetics. Leukemia, Myeloid, Acute / genetics

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16321221.001).

[ISSN] 0376-2491

[Journal-full-title] Zhonghua yi xue za zhi

[ISO-abbreviation] Zhonghua Yi Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Most of these patients are ventilated through endotracheal tubes (ETTs), others through laryngeal mask airways (LMAs).

The cuffs of both ETTs and LMAs inflate with increases in altitude as barometric pressure decreases (30 mbar/1000 feet).

METHODS: The change in dimensions of the inflated cuffs of a size 8 ETT and a size 5 LMA were measured with digital callipers at 1000 feet intervals in the unpressurised cabin of an Agusta 109 helicopter used by the Warwickshire and Northamptonshire Air Ambulance.

RESULTS: A linear expansion in cuff dimensions as a function of altitude increase was identified.

CONCLUSION: The data for LMA cuff expansion failed to show significant correlation with altitude change.

Further work is required to determine a similar rule of thumb for LMA cuff deflation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anaesthesia. 2000 Dec;55(12):1179-84 [11121927.001]

[Cites] Anaesthesia. 2002 Apr;57(4):374-8 [11939997.001]

[Cites] Anaesthesia. 2004 Mar;59(3):252-4 [14984523.001]

[Cites] Anaesthesia. 1975 Jan;30(1):4-11 [1115341.001]

[Cites] Br Med J (Clin Res Ed). 1984 Mar 31;288(6422):965-8 [6423162.001]

[Cites] J Trauma. 1999 Aug;47(2):352-7 [10452473.001]

[CommentIn] Emerg Med J. 2007 Aug;24(8):605 [17652705.001]

(PMID = 17351218.001).

[ISSN] 1472-0213

[Journal-full-title] Emergency medicine journal : EMJ

[ISO-abbreviation] Emerg Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC2660019

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Spinal osteomyelitis due to Aspergillus flavus in a child: a rare complication after haematopoietic stem cell transplantation.

We report the case of a child affected by acute myeloid leukaemia who was treated with allogeneic haematopoietic stem cell transplantation and developed cervicothoracic spinal osteomyelitis due to Aspergillus flavus.

The diagnosis was difficult on a clinical basis, but made possible by conventional radiography and MRI.

[MeSH-major] Aspergillosis / complications. Hematopoietic Stem Cell Transplantation / adverse effects. Osteomyelitis / microbiology. Spinal Diseases / microbiology

[MeSH-minor] Aspergillus flavus / isolation & purification. Bronchoalveolar Lavage. Diagnosis, Differential. Fatal Outcome. Fever / etiology. Humans. Hydrocephalus / etiology. Infant. Leukemia, Myeloid, Acute / surgery. Magnetic Resonance Imaging. Male. Radiography. Rare Diseases. Recurrence. Spine / diagnostic imaging. Spine / pathology

Genetic Alliance. consumer health - Osteomyelitis.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Aspergillosis.

MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Pediatr Radiol. 2003 Jul;33(7):453-60 [12739082.001]

[Cites] Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5 [9564455.001]

[Cites] J Infect. 2000 Jul;41(1):97-100 [11041713.001]

[Cites] Blood. 2002 Dec 15;100(13):4358-66 [12393425.001]

[Cites] Acta Orthop Belg. 1993;59(3):306-14 [8237349.001]

[Cites] Pediatrics. 1994 May;93(5):830-5 [8165091.001]

[Cites] Pediatr Neurosurg. 2001 Jul;35(1):18-23 [11490186.001]

[Cites] Clin Infect Dis. 2001 Jan;32(1):9-16 [11112668.001]

(PMID = 18392819.001).

[ISSN] 0301-0449

[Journal-full-title] Pediatric radiology

[ISO-abbreviation] Pediatr Radiol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

Complete loss or deletion of the long arm of chromosome 5 is frequent in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML).

This study is a comprehensive analysis of previously implicated and novel genes for epigenetic inactivation in AML and MDS.

In 146 AML cases, methylation of CTNNA1 was frequent, and more common in AML patients with 5q deletion (31%) than those without 5q deletion (14%), whereas no methylation of other 5q genes was observed.

In 31 MDS cases, CTNNA1 methylation was only found in high-risk MDS (>or=RAEB2), but not in low-risk MDS (<RAEB2), indicating that CTNNA1 methylation might be important in the transformation of MDS to AML.

CTNNA1 expression was lowest in AML/MDS patients with CTNNA1 methylation, although reduced expression was found in some patients without promoter methylation.

Repressive chromatin marks (H3K27me3) at the promoter were identified in CTNNA1-repressed AML cell lines and primary leukemias, with the most repressive state correlating with DNA methylation.

These results suggest progressive, acquired epigenetic inactivation at CTNNA1, including histone modifications and promoter CpG methylation, as a component of leukemia progression in patients with both 5q- and non-5q- myeloid malignancies.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Surg Oncol. 2007 Feb 1;95(2):148-55 [17262732.001]

[Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]

[Cites] Blood. 2007 Jul 15;110(2):719-26 [17420284.001]

[Cites] Nature. 2008 Jan 17;451(7176):335-9 [18202658.001]

[Cites] Br J Haematol. 2008 Feb;140(3):267-78 [18217896.001]

[Cites] Cancer Res. 2008 Apr 15;68(8):2764-72 [18413743.001]

[Cites] Clin Cancer Res. 2000 Nov;6(11):4243-8 [11106238.001]

[Cites] Nature. 2001 Jan 11;409(6817):207-11 [11196646.001]

[Cites] Leuk Res. 2001 Oct;25(10):917-25 [11532526.001]

[Cites] Blood. 2001 Nov 15;98(10):2935-41 [11698274.001]

[Cites] Blood. 2002 Jun 15;99(12):4638-41 [12036901.001]

[Cites] Cancer Lett. 2002 Nov 8;185(1):1-12 [12142073.001]

[Cites] Hematol Oncol. 2002 Dec;20(4):167-76 [12469326.001]

[Cites] Leuk Res. 2003 Jul;27(7):567-9 [12681354.001]

[Cites] Genes Chromosomes Cancer. 2003 Nov;38(3):249-52 [14506699.001]

[Cites] Leukemia. 2004 Jan;18(1):113-9 [14586479.001]

[Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]

[Cites] Blood. 1986 Nov;68(5):1101-7 [3094604.001]

[Cites] Blood. 1987 Dec;70(6):1705-12 [3315038.001]

[Cites] Blood. 1993 Nov 1;82(9):2611-6 [8219215.001]

[Cites] Cancer Res. 1994 Jan 1;54(1):291-6 [8261454.001]

[Cites] Blood. 1994 Nov 15;84(10):3253-60 [7949083.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7406-10 [7638206.001]

[Cites] Gastroenterology. 1996 Jan;110(1):52-7 [8536888.001]

[Cites] Cancer Res. 1996 Feb 1;56(3):612-5 [8564980.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]

[Cites] Blood. 1996 Oct 1;88(7):2665-70 [8839861.001]

[Cites] Cancer Res. 1997 Mar 1;57(5):837-41 [9041182.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6948-53 [9192672.001]

[Cites] Leukemia. 1997 Aug;11(8):1187-92 [9264367.001]

[Cites] Cancer Res. 1997 Sep 1;57(17):3779-83 [9288787.001]

[Cites] Blood. 1998 Apr 15;91(8):2985-90 [9531610.001]

[Cites] Blood. 1999 Oct 1;94(7):2445-51 [10498617.001]

[Cites] World J Gastroenterol. 2005 Jun 14;11(22):3468-72 [15948257.001]

[Cites] Leukemia. 2005 Jul;19(7):1224-8 [15902281.001]

[Cites] Ann Hematol. 2005 Dec;84 Suppl 1:39-46 [16231140.001]

[Cites] Eur J Haematol. 2006 Jan;76(1):23-32 [16343268.001]

[Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]

[Cites] Cancer Res. 2006 Apr 1;66(7):3541-9 [16585178.001]

[Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]

[Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]

[Cites] Blood. 2000 Apr 1;95(7):2372-7 [10733509.001]

[Cites] Mol Pathol. 2000 Aug;53(4):184-7 [11040940.001]

[Cites] Nat Cell Biol. 2006 May;8(5):532-8 [16570078.001]

[Cites] J Clin Oncol. 2006 Jun 1;24(16):2576-82 [16735711.001]

[Cites] Haematologica. 2006 Aug;91(8):1147-8 [16870548.001]

[Cites] Nat Med. 2007 Jan;13(1):78-83 [17159988.001]

[Cites] Leukemia. 2007 May;21(5):1026-34 [17330099.001]

(PMID = 19826047.001).

[ISSN] 1538-7445

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA058184-090013; United States / NCI NIH HHS / CA / P50 CA058184; United States / NCI NIH HHS / CA / P50 CA058184-090013

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CTNNA1 protein, human; 0 / Chromatin; 0 / RNA, Messenger; 0 / alpha Catenin; EC 1.13.12.- / Luciferases

[Other-IDs] NLM/ NIHMS142652; NLM/ PMC3081599

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Drug delivery in acute myeloid leukemia.

BACKGROUND: Acute myeloid leukemia was among the first malignancies to be cured by drug therapy alone, but overall survival rates remain unsatisfactory and have changed little over the past 20 years.

OBJECTIVE: We have chosen acute myeloid leukemia as a disease prototype to review established and novel targeted approaches in leukemia treatment.

CONCLUSION: While the toxicity profile of chemotherapeutics has been improved by liposomal formulations and antibody conjugation for leukemia-directed uptake, their efficacy has probably not changed significantly.

Further improvements may result from the characterization of novel acute myeloid leukemia (AML) cell surface receptors and of leukemic stem cells, as well as from the design of leukemia-targeted gene therapy vectors.

[MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Drug Delivery Systems. Genetic Therapy. Humans. Integrin alpha4beta1 / antagonists & inhibitors. Leukemia, Myeloid, Acute / drug therapy. Liposomes. Neoplastic Stem Cells / drug effects. Sialic Acid Binding Ig-like Lectin 3

Genetic Alliance. consumer health - Leukemia, Myeloid.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18532921.001).

[ISSN] 1742-5247

[Journal-full-title] Expert opinion on drug delivery

[ISO-abbreviation] Expert Opin Drug Deliv

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Integrin alpha4beta1; 0 / Liposomes; 0 / Sialic Acid Binding Ig-like Lectin 3

[Number-of-references] 114

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Selective killing of leukemia and lymphoma cells ectopically expressing hCGbeta by a conjugate of curcumin with an antibody against hCGbeta subunit.

EXPERIMENTAL DESIGN: The study was carried out on MOLT-4 and U-937 cells expressing hCGbeta and on peripheral blood leukocytes of acute myeloid leukemia (AML) patients.

RESULTS: The antibody did not impair the growth of MOLT-4 and U-937 cells in culture.

Its conjugate with curcumin, however, was lethal to both cell lines.

The immunoconjugate killed tumor cells bearing the CD33 marker of an AML patient expressing hCGbeta but did not have a similar action on cells of another AML patient with the CD13 marker but who was negative for hCGbeta.

[MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / metabolism. Curcumin / metabolism. Leukemia / drug therapy. Lymphoma / drug therapy

[MeSH-minor] Aged. Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Cell Separation. Drug Design. Female. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / metabolism. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Sialic Acid Binding Ig-like Lectin 3. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. U937 Cells

MedlinePlus Health Information. consumer health - Leukemia.

MedlinePlus Health Information. consumer health - Lymphoma.

Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

Hazardous Substances Data Bank. CURCUMIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19127081.001).

[ISSN] 1423-0232

[Journal-full-title] Oncology

[ISO-abbreviation] Oncology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; IT942ZTH98 / Curcumin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: We used modeling techniques to assess the cost-effectiveness of posaconazole versus FLU or ITRA in the prevention of IFIs among patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) and chemotherapy-induced neutropenia.

CONCLUSIONS: We conclude that posaconazole is very likely to be a cost-effective alternative to FLU or ITRA in the prevention of IFIs among neutropenic patients with AML and MDS, and may result in cost savings.

MedlinePlus Health Information. consumer health - Fungal Infections.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Itraconazole .

Hazardous Substances Data Bank. FLUCONAZOLE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19508661.001).

[ISSN] 1524-4733

[Journal-full-title] Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

[ISO-abbreviation] Value Health

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antifungal Agents; 304NUG5GF4 / Itraconazole; 8VZV102JFY / Fluconazole

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The majority of malignancies were distributed equally between T and B cell neoplasms and included lymphoblastic T cell lymphoma (LTCL), lymphoblastic B cell lymphoma (LBCL), diffuse large B cell lymphoma (DLBCL), the histiocyte/T cell rich variant of DLBCL (DLBCL-HA/T cell rich DLBCL), splenic marginal zone lymphoma (SMZL), follicular B cell lymphoma (FBL) and plasmacytoma (PCT).

Most of these neoplasms were highly similar to human diseases.

Also, some non-lymphoid malignancies such as acute myeloid leukemia (AML) and histiocytic sarcoma were found.

Interestingly, composite lymphomas, including Hodgkin-like lymphomas, were also detected that had CD30(+) Hodgkin/Reed-Sternberg (H/RS)-like cells, representing a tumor type not previously described in mice.

Thus, this DR4 line is a useful model to investigate common molecular mechanisms that may contribute to important neoplastic diseases in man.

[MeSH-major] Chimerism. Hematologic Neoplasms / immunology. Hematologic Neoplasms / pathology. Histocompatibility Antigens Class II / immunology. Hodgkin Disease / immunology. Hodgkin Disease / pathology

[MeSH-minor] Animals. Antigens, CD30 / metabolism. Base Sequence. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Mice. Mice, Transgenic. Molecular Sequence Data. Reed-Sternberg Cells / pathology. Survival Analysis. Transgenes / genetics

MedlinePlus Health Information. consumer health - Hodgkin Disease.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]

[Cites] Diagn Mol Pathol. 2002 Mar;11(1):2-8 [11854595.001]

[Cites] Oncogene. 2002 Sep 26;21(43):6559-66 [12242653.001]

[Cites] Am J Surg Pathol. 2002 Nov;26(11):1458-66 [12409722.001]

[Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]

[Cites] Am J Surg Pathol. 2003 Dec;27(12):1577-80 [14657719.001]

[Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W435-40 [15215425.001]

[Cites] Methods Cell Biol. 1989;30:353-77 [2494418.001]

[Cites] Int J Cancer. 1992 Dec 2;52(6):887-91 [1459730.001]

[Cites] J Exp Med. 1993 May 1;177(5):1257-68 [8386741.001]

[Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4319-23 [8483950.001]

[Cites] Blood. 1993 Aug 15;82(4):1247-56 [8353287.001]

[Cites] J Exp Med. 1995 Apr 1;181(4):1587-91 [7699339.001]

[Cites] Annu Rev Immunol. 1995;13:417-35 [7612230.001]

[Cites] Eur J Immunol. 1995 Oct;25(10):2813-7 [7589076.001]

[Cites] J Exp Med. 1996 Jun 1;183(6):2635-44 [8676084.001]

[Cites] Ann Oncol. 1996;7 Suppl 4:27-30 [8836405.001]

[Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]

[Cites] N Engl J Med. 1999 Apr 22;340(16):1239-47 [10210707.001]

[Cites] Exp Hematol. 1999 Apr;27(4):682-8 [10210326.001]

[Cites] Histopathology. 2005 Feb;46(2):217-28 [15693895.001]

[Cites] Cancer Res. 2005 Feb 15;65(4):1306-15 [15735016.001]

[Cites] Mutat Res. 2005 Jul 1;574(1-2):3-21 [15914203.001]

[Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]

[Cites] Exp Toxicol Pathol. 2006 Jul;57(5-6):377-81 [16713211.001]

[Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1213-24 [16815105.001]

[Cites] Pathol Biol (Paris). 2007 Feb;55(1):73-83 [16815642.001]

[Cites] Cell Cycle. 2007 Mar 1;6(5):543-5 [17329976.001]

[Cites] Toxicol Pathol. 2007 Apr;35(3):366-75 [17455084.001]

[Cites] Curr Protoc Hum Genet. 2001 May;Chapter 4:Unit4.10 [18428279.001]

[Cites] Immunol Rev. 1999 Dec;172:335-43 [10631958.001]

[Cites] Leukemia. 2000 Jul;14(7):1174-84 [10914539.001]

[Cites] Nucleic Acids Res. 2001 Jan 1;29(1):207-9 [11125093.001]

[Cites] Cytometry. 2001 Feb 1;43(2):101-9 [11169574.001]

[Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]

(PMID = 20046882.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD30; 0 / Histocompatibility Antigens Class II

[Other-IDs] NLM/ PMC2796171

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Achyrocline satureioides (LAM.) DC (Marcela): antimicrobial activity on Staphylococcus spp. and immunomodulating effects on human lymphocytes.

Achyrocline satureioides (LAM.

They were isolated from 18 patients with acne lesions and from 7 patients infected with Staphylococcus spp. (5 strains were taken from catheters and 2 from wounds).

On the other hand, cultures of lymphocytes were made from those patients who displayed infections caused by Staphylococcus spp. and from 12 control non-infected individuals.

The A. satureiodes decoction inhibited 95% of the isolated Staphylococcus spp. strains and stimulated the lymphocyte expansion, of which 40% were CD8+ T cells.

[MeSH-minor] Acne Vulgaris / microbiology. Adolescent. Adult. Bacteremia / microbiology. Catheterization. Cells, Cultured / drug effects. Drug Evaluation, Preclinical. Humans. Lymphocyte Activation / drug effects. Phytohemagglutinins / pharmacology. Plant Leaves / chemistry. Staphylococcal Infections / microbiology. Staphylococcal Skin Infections / microbiology. Wound Infection / microbiology

MedlinePlus Health Information. consumer health - Antibiotics.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18293658.001).

[ISSN] 0187-4640

[Journal-full-title] Revista latinoamericana de microbiología

[ISO-abbreviation] Rev. Latinoam. Microbiol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Mexico

[Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anti-Bacterial Agents; 0 / Phytohemagglutinins; 0 / Plant Extracts

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Volatile components of Centaurea eryngiodes Lam. and Centaurea iberica Trev.var. hermonis Bois. Lam.,two Asteraceae growing wild in Lebanon.

The volatile components of the flowerheads of Centaurea eryngioides Lam. and Centaurea iberica Trev. var. hermonis Boiss. Lam. were obtained by hydrodistillation and identified by GC and GC-MS.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16317829.001).

[ISSN] 1478-6419

[Journal-full-title] Natural product research

[ISO-abbreviation] Nat. Prod. Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Oils, Volatile; 0 / Plant Oils

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.

The combination of fludarabine, high-dose cytarabine, gemtuzumab ozogamicin, and granulocyte colony-stimulating factor (G-CSF), the FLAG-GO protocol, has resulted in excellent response rates and superior relapse-free survival as first-line therapy for patients with core binding factor acute myeloid leukemia (AML).

A side effect of administration of G-CSF is an increase in peripheral white blood cell count and blast cell percentage during the recovery phase of the bone marrow after induction chemotherapy.

A 60-year-old man with inversion 16 AML was admitted for induction chemotherapy with the FLAG-GO protocol at our institution.

Our case report underscores the importance of recognizing this phenomenon associated with the administration of G-CSF, and waiting for 5-7 days before administering re-induction therapy or classifying the disease as primary refractory AML.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. VIDARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20709669.001).

[ISSN] 2152-2669

[Journal-full-title] Clinical lymphoma, myeloma & leukemia

[ISO-abbreviation] Clin Lymphoma Myeloma Leuk

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30 CA016672

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Core Binding Factors; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; FLAG protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

With regard to hematological malignancies a stimulating effect of VEGF for proliferation, survival and migration of leukemia cells could be demonstrated.

Bone marrow of leukemia patients shows an increased microvessel density as well as VEGF expression.

Complete remissions in acute myeloid leukemia (AML) have been reported by targeting the receptor tyrosine kinase system of VEGF.

While the pathophysiology behind the contribution of VEGF to leukemia progression is not yet completely understood, VEGF and its receptors may provide promising targets not only in solid tumors but also hematological malignancies such as AML.

[MeSH-minor] Cell Proliferation. Cell Survival. Disease Progression. Humans

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17305503.001).

[ISSN] 1873-5592

[Journal-full-title] Current drug targets

[ISO-abbreviation] Curr Drug Targets

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor

[Number-of-references] 226

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.

[MeSH-major] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Leukemia, Myeloid, Acute / complications. Liposomes / therapeutic use. Mucormycosis / drug therapy. Rhizomucor / isolation & purification. Triazoles / therapeutic use

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. AMPHOTERICIN B .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16961579.001).

[ISSN] 0933-7407

[Journal-full-title] Mycoses

[ISO-abbreviation] Mycoses

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antifungal Agents; 0 / Liposomes; 0 / Triazoles; 0 / liposomal amphotericin B; 6TK1G07BHZ / posaconazole; 7XU7A7DROE / Amphotericin B

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Expression of mitosis checkpoint gene CHFR in acute leukemia].

OBJECTIVE: To investigate the expression of mitosis checkpoint gene CHFR in adult patients with acute leukemia (AL) and its clinical significance.

METHODS: Four ml of bone marrow was extracted from 65 AL patients, 38 males and 27 females, with the median age of 35, 43 with acute myelocytic leukemia (AML) and 22 with acute lymphocytic leukemia (ALL), 45 de novo patients and 20 recurrent patients, and 8 normal donor of allogeneic bone marrow transplantation as controls.

The cell cycle was examined by flow cytometric analysis.

(1) The levels of CHFR protein and mRNA were correlated with the cumulative percentages of cells in S phases. (2) The expression level of CHFR protein in 40.6% (13/32) of the AL patients and that of the CHFR mRNA in 60.0% (27/45) of the AL patients were both significantly lower than those of the normal controls. (3) The mean expression level of CHFR protein in the recurrent acute lymphoblastic leukemia (ALL) was 0.71, significantly higher than that of the de novo group (0.38, t = 2.54, P = 0.017). (4) The complete remission (CR) rates in the AL patients with high expression levels of CHFR protein and mRNA were 30.2% and 42.4% respectively, significantly lower than those in the AL patients with low expression levels (88.6% and 85.4% respectively, both P < 0.05).

CONCLUSION: By affecting mitotic checkpoint function, CHFR inactivation plays a key role in tumorigenesis in adult patients with acute leukemia.

Moreover, the aberrant expression of CHFR appears to be a good molecular marker to predict the sensitivity of acute leukemia to chemotherapy.

[MeSH-major] Cell Cycle Proteins / biosynthesis. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

[MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Cell Cycle. Child. Drug Resistance. Female. HL-60 Cells. Humans. Male. Middle Aged. Mitosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16029562.001).

[ISSN] 0376-2491

[Journal-full-title] Zhonghua yi xue za zhi

[ISO-abbreviation] Zhonghua Yi Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

To elucidate host factors contributing to the poor response of adoptively transferred tumor-reactive cytotoxic T lymphocytes (CTLs), we used a systemic model of murine acute myeloid leukemia (AML).

AML progression resulted in a progressive regulatory T-cell (Treg) accumulation in disease sites.

The adoptive transfer of in vitro-generated, potently lytic anti-AML-reactive CTLs failed to reduce disease burden or extend survival.

Compared with non-AML-bearing hosts, transferred CTLs had reduced proliferation in AML sites of metastases.

Treg depletion by a brief course of interleukin-2 diphtheria toxin (IL-2DT) transiently reduced AML disease burden but did not permit long-term survival.

In contrast, IL-2DT prevented anti-AML CTL hypoproliferation, increased the number of transferred CTLs at AML disease sites, reduced AML tumor burden, and resulted in long-term survivors that sustained an anti-AML memory response.

These data demonstrated that Tregs present at AML disease sites suppress adoptively transferred CTL proliferation, limiting their in vivo expansion, and Treg depletion before CTL transfer can result in therapeutic efficacy in settings of substantial pre-existing tumor burden in which antitumor reactive CTL infusion alone has proven ineffective.

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Exp Hematol. 2006 Oct;34(10):1403-12 [16982333.001]

[Cites] Cancer Immunol Immunother. 2007 Jan;56(1):48-59 [16612596.001]

[Cites] Haematologica. 2007 Jan;92(1):72-80 [17229638.001]

[Cites] Cancer Sci. 2007 Mar;98(3):416-23 [17270031.001]

[Cites] Immunol Res. 2006;36(1-3):73-82 [17337768.001]

[Cites] J Clin Invest. 2004 Nov;114(10):1389-97 [15545986.001]

[Cites] J Clin Invest. 2004 Nov;114(10):1398-403 [15545987.001]

[Cites] Bone Marrow Transplant. 2004 Dec;34(11):923-8 [15361911.001]

[Cites] Blood Rev. 2005 Nov;19(6):289-300 [16275419.001]

[Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]

[Cites] Cancer Immunol Immunother. 2006 Jan;55(1):68-75 [15891884.001]

[Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]

[Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]

[Cites] Methods. 2003 Oct;31(2):127-34 [12957570.001]

[Cites] Cancer Res. 2004 Jun 1;64(11):3914-21 [15173002.001]

[Cites] J Allergy Clin Immunol. 2004 Aug;114(2):296-301 [15316506.001]

[Cites] Blood. 1995 Oct 1;86(7):2732-40 [7670112.001]

[Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]

[Cites] Blood. 1999 Aug 15;94(4):1201-8 [10438707.001]

[Cites] Curr Opin Oncol. 2006 Mar;18(2):107-14 [16462177.001]

[Cites] J Immunol. 2006 Mar 15;176(6):3342-9 [16517701.001]

[Cites] Int J Cancer. 2007 Jun 15;120(12):2723-33 [17315189.001]

[Cites] Cancer Immunol Immunother. 2007 Jul;56(7):943-57 [17180671.001]

[Cites] Blood. 2007 Apr 1;109(7):2871-7 [17164341.001]

[Cites] J Immunol. 2007 Jun 1;178(11):6840-8 [17513732.001]

[Cites] Gastroenterology. 2007 Jun;132(7):2328-39 [17570208.001]

[Cites] Blood. 2007 Jul 1;110(1):409-17 [17374741.001]

[Cites] Cancer Immun. 2007;7:10 [17591743.001]

[Cites] Exp Oncol. 2007 Jun;29(2):102-5 [17704740.001]

[Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5243-8 [17875751.001]

[Cites] J Immunol. 2007 Oct 1;179(7):4919-28 [17878392.001]

[Cites] Blood. 2007 Nov 1;110(9):3480-8 [17606761.001]

[Cites] Blood. 2007 Nov 1;110(9):3192-201 [17616639.001]

[Cites] Cell Death Differ. 2008 Jan;15(1):70-9 [18007660.001]

[Cites] Immunity. 2007 Dec;27(6):985-97 [18082432.001]

[Cites] Cytotherapy. 2007;9(8):755-70 [17917887.001]

[Cites] Int J Cancer. 2008 Apr 15;122(8):1794-802 [18076066.001]

[Cites] Curr Med Chem. 2008;15(10):991-6 [18393856.001]

[Cites] J Immunother. 2008 Feb-Mar;31(2):121-31 [18481382.001]

[Cites] J Immunother. 2008 Feb-Mar;31(2):189-98 [18481388.001]

[Cites] J Immunol. 2008 Sep 1;181(5):3291-300 [18714001.001]

[Cites] J Exp Med. 2008 Sep 1;205(9):2125-38 [18725522.001]

[Cites] Best Pract Res Clin Haematol. 2008 Sep;21(3):455-66 [18790449.001]

[Cites] Biol Blood Marrow Transplant. 2008 Oct;14(10):1088-99 [18804038.001]

[Cites] J Immunother. 2008 Oct;31(8):742-51 [18779745.001]

[Cites] J Exp Med. 2008 Sep 29;205(10):2221-34 [18794336.001]

[Cites] Am J Hematol. 2008 Oct;83(10):771-7 [18756547.001]

[Cites] Int J Immunopathol Pharmacol. 2008 Jul-Sep;21(3):493-500 [18831916.001]

[Cites] Transplantation. 2008 Oct 27;86(8):1125-34 [18946352.001]

[Cites] Expert Opin Biol Ther. 2008 Dec;8(12):1897-920 [18990077.001]

[Cites] J Immunol. 2008 Dec 15;181(12):8209-13 [19050237.001]

[Cites] Scand J Immunol. 2008 Dec;68(6):572-8 [19055696.001]

[Cites] Clin Cancer Res. 2008 Dec 15;14(24):8270-8 [19088044.001]

[Cites] J Clin Oncol. 2009 Jan 10;27(2):186-92 [19064967.001]

[Cites] Blood. 2009 Feb 12;113(7):1581-8 [18974373.001]

[Cites] Clin Cancer Res. 2009 May 15;15(10):3325-32 [19417016.001]

(PMID = 19724059.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA120409-03; United States / NCI NIH HHS / CA / CA120409-03; United States / NCI NIH HHS / CA / R01 CA120409; United States / NCI NIH HHS / CA / R01 CA72669; United States / NHLBI NIH HHS / HL / R01 HL056067; United States / NCI NIH HHS / CA / R01 CA072669

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 0 / interleukin 2-diphtheria toxin

[Other-IDs] NLM/ PMC2773484

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [The diagnosis of acute myeloid leukaemia enhanced by using DNA microarrays].

[Transliterated title] Diagnostiek van acute myeloïde leukemie in een stroomversnelling door toepassing van DNA-microarrays.

Recently, two studies have shown that the use ofgene-expression profiling using DNA microarrays or DNA chips may improve the classification of acute myeloid leukaemia (AML).

In both studies, cluster analyses based on the molecular signatures defined known subgroups as well as novel subgroups of AML.

Chromosomal lesions, mutations, and abnormal gene expression with prognostic value determined the clustering.

In fact, gene-expression profiling recognized leukaemias with certain chromosomal aberrations that had been missed by routine cytogenetics.

Thus, gene-expression profiling allows a comprehensive classification of AML that includes previously-identified genetically-defined as well as novel prognostically-relevant subgroups.

[MeSH-major] Chromosome Aberrations. Gene Expression Profiling / methods. Leukemia, Myeloid / diagnosis. Leukemia, Myeloid / genetics. Oligonucleotide Array Sequence Analysis

[MeSH-minor] Acute Disease. Cluster Analysis. Cytogenetic Analysis. Humans

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Ned Tijdschr Geneeskd. 2005 Mar 19;149(12):618-22 [15813427.001]

(PMID = 15813428.001).

[ISSN] 0028-2162

[Journal-full-title] Nederlands tijdschrift voor geneeskunde

[ISO-abbreviation] Ned Tijdschr Geneeskd

[Language] dut

[Publication-type] English Abstract; Journal Article

[Publication-country] Netherlands

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

A new hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was effective in predicting outcomes among patients with hematologic malignancies who underwent HCT at Fred Hutchinson Cancer Research Center (FHCRC).

Here, we compared the performance of the HCT-CI to 2 other indices and then tested its capacity to predict outcomes among 2 cohorts of patients diagnosed with a single disease entity, acute myeloid leukemia in first complete remission, who underwent transplantation at either FHCRC or M. D.

Genetic Alliance. consumer health - Leukemia, Myeloid.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Laryngoscope. 2000 Apr;110(4):593-602 [10764003.001]

[Cites] Tohoku J Exp Med. 2006 Jul;209(3):217-28 [16778368.001]

[Cites] J Epidemiol Community Health. 2000 Jun;54(6):431-6 [10818118.001]

[Cites] Crit Rev Oncol Hematol. 2000 Sep;35(3):181-200 [10960800.001]

[Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]

[Cites] J Clin Oncol. 2001 Apr 15;19(8):2134-41 [11304765.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):357-64 [12243808.001]

[Cites] Ann Oncol. 2002 Oct;13(10):1621-7 [12377652.001]

[Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]

[Cites] Am J Kidney Dis. 2003 Jul;42(1):125-32 [12830464.001]

[Cites] Blood. 2003 Aug 15;102(4):1232-40 [12714526.001]

[Cites] Zentralbl Chir. 2003 Nov;128(11):970-6 [14669119.001]

[Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64 [16920562.001]

[Cites] Haematologica. 2006 Nov;91(11):1513-22 [17082009.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2348-54 [17164355.001]

[Cites] J Clin Oncol. 2007 Jan 1;25(1):25-31 [17146105.001]

[Cites] Bone Marrow Transplant. 2007 Jan;39(2):71-87 [17213849.001]

[Cites] Cancer Control. 2007 Jan;14(1):13-22 [17242667.001]

[Cites] Curr Opin Hematol. 2007 Mar;14(2):145-51 [17255792.001]

[Cites] Br J Haematol. 2007 Feb;136(4):624-7 [17223919.001]

[Cites] J Chronic Dis. 1974 Sep;27(7-8):387-404 [4436428.001]

[Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]

[Cites] Br J Rheumatol. 1988 Feb;27(1):44-7 [3422170.001]

[Cites] Chest. 1992 May;101(5):1257-64 [1582281.001]

[Cites] Chest. 1992 Nov;102(5):1484-90 [1330449.001]

[Cites] Br J Cancer. 1997;76(2):251-5 [9231927.001]

[Cites] Laryngoscope. 1997 Nov;107(11 Pt 1):1469-75 [9369392.001]

[Cites] J Clin Oncol. 1998 Apr;16(4):1582-7 [9552069.001]

[Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):94-7 [9666800.001]

[Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]

[Cites] Blood. 1998 Nov 15;92(10):3515-20 [9808542.001]

[Cites] J Clin Epidemiol. 1999 Jan;52(1):27-37 [9973071.001]

[Cites] Ann Hematol. 1999 Jul;78(7):315-9 [10466443.001]

[Cites] Women Health. 1999;29(3):1-12 [10466507.001]

[Cites] Ear Nose Throat J. 1999 Aug;78(8):578, 581-4 [10485151.001]

[Cites] Eur J Cancer. 2005 May;41(7):1051-7 [15862755.001]

[Cites] Am J Respir Crit Care Med. 2005 Aug 1;172(3):384-90 [15894602.001]

[Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]

[Cites] Best Pract Res Clin Haematol. 2006;19(2):333-9 [16516131.001]

[Cites] Med Care. 2000 May;38(5):482-93 [10800975.001]

[Cites] J Am Coll Cardiol. 2004 Feb 18;43(4):576-82 [14975466.001]

[Cites] Leukemia. 2004 Apr;18(4):809-16 [14762444.001]

[Cites] JAMA. 2004 May 26;291(20):2441-7 [15161894.001]

[Cites] Int J Artif Organs. 2004 Apr;27(4):330-6 [15163067.001]

[Cites] Am J Epidemiol. 2004 Jun 15;159(12):1160-7 [15191933.001]

[Cites] Int J Hematol. 2004 Jun;79(5):495-500 [15239403.001]

[Cites] Stroke. 2004 Aug;35(8):1941-5 [15232123.001]

[Cites] Leuk Lymphoma. 2004 Jun;45(6):1103-9 [15359988.001]

[Cites] ORL J Otorhinolaryngol Relat Spec. 2004 Jul-Aug;66(4):180-5 [15467342.001]

[Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]

[Cites] Semin Hematol. 2006 Apr;43(2):107-17 [16616044.001]

(PMID = 17873123.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / CA78902; United States / NHLBI NIH HHS / HL / R00 HL088021; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / P01 CA078902; United States / NHLBI NIH HHS / HL / K99 HL088021; United States / NHLBI NIH HHS / HL / HL088021

[Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC2234788

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The International Prognostic Scoring System (IPSS) groups Low/Intermediate-1 (Low/Int-1) had longer response duration than Int-2/High (25 versus 7 months, P = .002).

The time until 25% developed acute myeloid leukemia (AML) was longer in the good and intermediate predictive groups for erythroid response compared with the poor predictive group (52 versus 13 months, P = .008).

Only 1 of 20 long-term responders developed AML.

There was no difference in survival (odds ratio [OR], 0.9; 95% confidence interval [CI], 0.7-1.2; P = .55) or risk of AML evolution (OR, 1.3; 95% CI, 0.7-2.2; P = .40) between treated and untreated patients.

Patients with high/intermediate probability of response and with IPSS Low/Int-1 show frequent and durable responses without adverse effects on outcome, while other patients should not be considered candidates for this treatment.

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Cell Transformation, Neoplastic. Female. Humans. Leukemia, Myeloid / etiology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Survival Analysis. Treatment Outcome

Genetic Alliance. consumer health - Anemia.

MedlinePlus Health Information. consumer health - Anemia.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15840690.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 11096-26-7 / Erythropoietin; 143011-72-7 / Granulocyte Colony-Stimulating Factor

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The FcgammaRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation.

Graft-versus-host disease (GVHD) is a serious complication of allogeneic stem cell transplantation for hematologic diseases.

Polymorphisms are known for FcgammaRIIa, and this molecule is present on endothelial, dendritic, and Langerhans cells.

Donor cells reacting against the patient as GVHD can also react against the malignancy of the patient, and this is known as the graft-versus-leukemia (GVL) effect.

Because the FcgammaRIIa molecule is also present on acute myeloid leukemia (AML) cells, an FcgammaRIIa mismatch could be a target for both GVHD and GVL.

We retrospectively studied 73 AML patients and analyzed the differences in GVHD and relapse incidence between patients with and without a pro-GVHD/GVL FcgammaRIIa allotype mismatch.

Univariate and multivariate analyses demonstrated the pro-GVHD mismatch to be a significant risk factor for the development of acute GVHD.

The relapse incidence was not significantly different for patients with or without the pro-GVL mismatch, although there was a trend for fewer relapses in standard-risk AML patients with the pro-GVL mismatch.

We conclude that the polymorphism of the FcgammaRIIa receptor may be a candidate target for acute GVHD.

[MeSH-major] Antigens, CD / genetics. Graft vs Host Disease / genetics. Hematopoietic Stem Cell Transplantation / adverse effects. Polymorphism, Genetic. Receptors, IgG / genetics

[MeSH-minor] Acute Disease. Adult. Aged. Analysis of Variance. Cohort Studies. Female. Graft vs Leukemia Effect / genetics. Graft vs Leukemia Effect / immunology. Humans. Incidence. Leukemia, Myeloid / complications. Leukemia, Myeloid / therapy. Male. Middle Aged. Recurrence. Retrospective Studies. Transplantation Immunology. Transplantation, Homologous

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15744239.001).

[ISSN] 1083-8791

[Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

[ISO-abbreviation] Biol. Blood Marrow Transplant.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / Fc gamma receptor IIA; 0 / Receptors, IgG

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples.

BACKGROUND: The accurate diagnosis of TB in HIV-infected patients, particularly with advanced immunosuppression, is difficult.

Recent studies indicate that a lipoarabinomannan (LAM) assay (Clearview-TB(R)-ELISA) may have some utility for the diagnosis of TB in HIV-infected patients; however, the precise subgroup that may benefit from this technology requires clarification.

The utility of LAM in sputum samples has, hitherto, not been evaluated.

METHODS: LAM was measured in sputum and urine samples obtained from 500 consecutively recruited ambulant patients, with suspected TB, from 2 primary care clinics in South Africa.

Culture positivity for M. tuberculosis was used as the reference standard for TB diagnosis.

Urine-LAM positivity was associated with HIV positivity (p = 0.007) and test sensitivity, although low, was significantly higher in HIV-infected compared to uninfected patients (21% versus 6%; p<0.001), and also in HIV-infected participants with a CD4 <200 versus >200 cells/mm(3) (37% versus 0%; p = 0.003).

Urine-LAM remained highly specific in all 3 subgroups (95%-100%).

25% of smear-negative but culture-positive HIV-infected patients with a CD4 <200 cells/mm(3) were positive for urine-LAM.

Sputum-LAM had good sensitivity (86%) but poor specificity (15%) likely due to test cross-reactivity with several mouth-residing organisms including actinomycetes and nocardia species.

CONCLUSIONS: These preliminary data indicate that in a high burden primary care setting the diagnostic usefulness of urine-LAM is limited, as a rule-in test, to a specific patient subgroup i.e. smear-negative HIV-infected TB patients with a CD4 count <200 cells/mm(3), who would otherwise have required further investigation.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - Tuberculosis.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Microbiol. 2000 Jun;38(6):2278-83 [10834989.001]

[Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):145-51 [19692904.001]

[Cites] Scand J Infect Dis. 2001;33(4):279-84 [11345220.001]

[Cites] Arch Intern Med. 2003 May 12;163(9):1009-21 [12742798.001]

[Cites] Semin Respir Infect. 2003 Dec;18(4):263-71 [14679475.001]

[Cites] Clin Chem. 2004 Mar;50(3):473-6 [14981027.001]

[Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]

[Cites] JAMA. 1982 May 14;247(18):2543-6 [7069920.001]

[Cites] J Immunol Methods. 1996 Apr 19;190(2):151-61 [8621950.001]

[Cites] Trans R Soc Trop Med Hyg. 2005 Dec;99(12):893-900 [16139316.001]

[Cites] Int J Tuberc Lung Dis. 2006 Jan;10(1):31-8 [16466034.001]

[Cites] Expert Rev Mol Diagn. 2006 May;6(3):423-32 [16706744.001]

[Cites] AIDS. 2007 Feb 19;21(4):423-32 [17301560.001]

[Cites] Lancet. 2007 Jun 16;369(9578):2042-9 [17574096.001]

[Cites] PLoS One. 2009;4(3):e4689 [19277111.001]

[Cites] Curr Opin Pulm Med. 2009 May;15(3):188-200 [19387262.001]

[Cites] J Clin Invest. 2009 May;119(5):1085-9 [19422099.001]

[Cites] Int J Tuberc Lung Dis. 2009 Aug;13(8):989-95 [19723379.001]

[Cites] BMC Infect Dis. 2009;9:141 [19715562.001]

[Cites] Int J Tuberc Lung Dis. 2009 Oct;13(10):1253-9 [19793430.001]

[Cites] Clin Chest Med. 2009 Dec;30(4):701-16, viii [19925962.001]

[Cites] AIDS. 2009 Sep 10;23(14):1875-80 [20108382.001]

[Cites] J Microbiol Methods. 2001 May;45(1):41-52 [11295196.001]

(PMID = 20352098.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] ENG

[Grant] None / None / / 89918; Canada / Canadian Institutes of Health Research / / 89918; Canada / Canadian Institutes of Health Research / / MOP-89918; United Kingdom / Medical Research Council / /

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC2844421

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Core binding factor acute myeloid leukemia.

Core binding factor (CBF) acute myeloid leukemia (AML) is cytogenetically defined by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), which are found in approximately 15% of all adult de novo AML cases.

Despite this molecular commonality, recent studies have demonstrated differences in genetic, clinical, and prognostic features between t(8;21) and inv(16)/t(16;16) AML, thereby supporting the notion that they represent two distinct biologic and clinical entities.

Furthermore, despite being considered as a more favorable AML risk group, only approximately half of the CBF AML patients are cured with current therapy, indicating the need for improved therapeutic approaches.

This review summarizes the most recent laboratory and clinical discoveries relevant to this subset of AML and how they are being applied for in an effort to improve the cure rate in patients with the disease.

[MeSH-major] Chromosome Inversion. Core Binding Factors / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Translocation, Genetic

[MeSH-minor] Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Humans. Neoplasm, Residual / diagnosis. Prognosis

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18692691.001).

[ISSN] 0093-7754

[Journal-full-title] Seminars in oncology

[ISO-abbreviation] Semin. Oncol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Core Binding Factors

[Number-of-references] 76

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor.

BACKGROUND: Therapy-related myeloid neoplasm (t-MN) is a distinct class of acute myeloid leukemia (AML) in the World Health Organization (WHO) classification.

Both AML and acute lymphoblastic leukemia (ALL) may develop after treatment for primary cancer.

Topoisomerase inhibitors are commonly used to treat breast cancer patients and are well-known for their effect on leukemogenesis of therapy-related acute leukemias (t-AL).

METHODS: We retrospectively evaluated bone marrow test results, chromosomal findings, and clinical characteristics of 12 patients who received topoisomerase inhibitors for breast cancer treatment and later developed acute leukemia.

Among them, 9 patients (75%, 9/12) were diagnosed with therapy-related AML (t-AML) and 3 patients (25%, 3/12) with therapy-related ALL (t-ALL).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2003 Apr 1;21(7):1195-204 [12663705.001]

[Cites] Semin Hematol. 1996 Jul;33(3):256-73 [8819235.001]

[Cites] J Clin Oncol. 2005 Jun 20;23(18):4179-91 [15961765.001]

[Cites] Zentralbl Gynakol. 2005 Aug;127(4):235-41 [16037905.001]

[Cites] Br J Haematol. 2007 Feb;136(4):590-6 [17367411.001]

[Cites] Br J Haematol. 2007 Jun;137(6):513-29 [17539774.001]

[Cites] Nat Rev Cancer. 2007 Nov;7(11):823-33 [17957188.001]

[Cites] Haematologica. 2007 Oct;92(10):1389-98 [17768113.001]

[Cites] Leuk Lymphoma. 2008 Feb;49(2):204-17 [18231906.001]

[Cites] Cancer Res. 2008 Dec 15;68(24):10024-7 [19074864.001]

[Cites] Blood. 2009 Jul 30;114(5):937-51 [19357394.001]

[Cites] Breast Cancer Res Treat. 2009 Dec;118(3):593-8 [19322652.001]

[Cites] Am J Clin Pathol. 2010 Jan;133(1):75-82 [20023261.001]

[Cites] Am J Med Sci. 2010 Jan;339(1):36-40 [19996729.001]

[Cites] Chem Biol Interact. 2010 Mar 19;184(1-2):39-45 [20026017.001]

[Cites] Korean J Lab Med. 2010 Jun;30(3):255-9 [20603585.001]

[Cites] Cancer. 2004 Oct 1;101(7):1529-36 [15378478.001]

[Cites] Br J Haematol. 1999 Sep;106(4):1037-40 [10520009.001]

(PMID = 21120206.001).

[ISSN] 2092-9129

[Journal-full-title] The Korean journal of hematology

[ISO-abbreviation] Korean J Hematol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Korea (South)

[Other-IDs] NLM/ PMC2983048

[Keywords] NOTNLM ; 11q23 / Breast cancer / Therapy-related acute myeloid leukemia / Topoisomerase inhibitors

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Body weight, 10th rib backfat (BF10), last rib backfat (LRF), and loin muscle area (LMA) were serially measured at 10, 13, 16, 19, 22, 24, and 26 wk of age.

At 26 wk of age, Duroc-sired progeny were heavier (143.4 vs. 132.7 kg, P < 0.001), had more BF10 (27.1 vs. 23.7 mm, P < 0.001) and LRF (21.2 vs. 19.2 mm, P < 0.001), but had similar LMA (46.4 vs. 47.1 cm2) compared with Pietrain-sired progeny.

Mean feed efficiency did not differ between breed of sire in any period of the study.

Random regression animal models with polynomial regression on week on-test were fitted to BW, BF10, LRF, LMA, FFTOLN, TOFAT, EBPRO, and EBLIPID from 10 to 26 wk of age.

Serial heritability estimates generally increased from 10 to 26 wk of age with ranges as follows: BW (0.05 to 0.39), BF10 (0.13 to 0.76), LRF (0.11 to 0.79), LMA (0.05 to 0.73), FFTOLN (0.07 to 0.16), TOFAT (0.19 to 0.45), EBPRO (0.02 to 0.55), and EBLIPID (0.12 to 0.60).

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16424252.001).

[ISSN] 1525-3163

[Journal-full-title] Journal of animal science

[ISO-abbreviation] J. Anim. Sci.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Aspergillus alliaceus and Aspergillus flavus co-infection in an acute myeloid leukemia patient.

We report a case of a pulmonary infection caused by Aspergillus flavus and Aspergillus alliaceus in an acute myeloid leukemia patient.

[MeSH-major] Aspergillosis / complications. Aspergillosis / microbiology. Aspergillus / isolation & purification. Aspergillus flavus / classification. Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / complications. Lung Diseases, Fungal / microbiology

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Aspergillosis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20392148.001).

[ISSN] 1460-2709

[Journal-full-title] Medical mycology

[ISO-abbreviation] Med. Mycol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Intergenic; 0 / Fungal Proteins; 0 / Tubulin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Intracellular NAD is essential for cell survival, and NAD depletion resulting from APO866 treatment elicits tumor cell death.

Here, we determine the in vitro and in vivo sensitivities of hematologic cancer cells to APO866 using a panel of cell lines (n = 45) and primary cells (n = 32).

Most cancer cells (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell lymphoma), but not normal hematopoietic progenitor cells, were sensitive to low concentrations of APO866 as measured in cytotoxicity and clonogenic assays.

The NAD depletion led to cell death.

At 96 hours, APO866-mediated cell death occurred in a caspase-independent mode, and was associated with mitochondrial dysfunction and autophagy.

Further, in vivo administration of APO866 as a single agent prevented and abrogated tumor growth in animal models of human AML, lymphoblastic lymphoma, and leukemia without significant toxicity to the animals.

[MeSH-minor] Animals. Cell Death / drug effects. Dose-Response Relationship, Drug. HL-60 Cells. Humans. Jurkat Cells. K562 Cells. Mice. Mice, Inbred BALB C. Mice, Nude. Tumor Cells, Cultured. U937 Cells. Xenograft Model Antitumor Assays

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Blood. 2009 Jun 4;113(23):6035-7; author reply 6037-8 [19498032.001]

(PMID = 19196867.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Acrylamides; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide; 0 / Piperidines; 0U46U6E8UK / NAD; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12 / nicotinamide phosphoribosyltransferase, human